Pfizer reduces scope of US biomanufacturing facility, contractor says
15 April 2024
Swedish contractor Skanska has announced the scope of a US-based biomanufacturing facility project has been reduced, as client Pfizer – a US-based pharmaceutical company – now seeks to pay the builder US$49 million instead of $215 million.
The Everett, Washington, US, skyline. (Image: Adobe Stock)
Skanska had finalised a contract with Seagen, a US-based biotechnology firm, in August of 2023, to build a 25,000m2 (269,098 sq ft) plant in Everett, Washington, USA.
The site was to include manufacturing, storage, shipping, office, and café spaces.
In December 2023, Pfizer purchased Seagen for more than $40 billion.
Just last month, Pfizer announced it was pulling the plug on Seagen’s Everett-based build, the cost for which had ballooned to more than $350 million, local media reported.
Last week, Skanska announced the scheme was resurrected, albeit with a smaller price tag.
“The initial contract with Seagen, which recently was acquired by Pfizer, was worth $215 million, about SEK 2.2 billion, and was announced August 4, 2023,” said Skanska. “The order reduction amounts to $49 million, about SEK 510 million, which will be deducted from the US order bookings for the first quarter 2024.”
Construction was originally slated to start this month, though an updated timetable for the current contracted work was not available.
STAY CONNECTED
Receive the information you need when you need it through our world-leading magazines, newsletters and daily briefings.
CONNECT WITH THE TEAM
